These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 26087189)
1. Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Heinemann A; Cullinane C; De Paoli-Iseppi R; Wilmott JS; Gunatilake D; Madore J; Strbenac D; Yang JY; Gowrishankar K; Tiffen JC; Prinjha RK; Smithers N; McArthur GA; Hersey P; Gallagher SJ Oncotarget; 2015 Aug; 6(25):21507-21. PubMed ID: 26087189 [TBL] [Abstract][Full Text] [Related]
2. HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. Gallagher SJ; Gunatilake D; Beaumont KA; Sharp DM; Tiffen JC; Heinemann A; Weninger W; Haass NK; Wilmott JS; Madore J; Ferguson PM; Rizos H; Hersey P Int J Cancer; 2018 May; 142(9):1926-1937. PubMed ID: 29210065 [TBL] [Abstract][Full Text] [Related]
3. The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells. Gallagher SJ; Mijatov B; Gunatilake D; Tiffen JC; Gowrishankar K; Jin L; Pupo GM; Cullinane C; Prinjha RK; Smithers N; McArthur GA; Rizos H; Hersey P J Invest Dermatol; 2014 Nov; 134(11):2795-2805. PubMed ID: 24906137 [TBL] [Abstract][Full Text] [Related]
4. Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Lai F; Guo ST; Jin L; Jiang CC; Wang CY; Croft A; Chi MN; Tseng HY; Farrelly M; Atmadibrata B; Norman J; Liu T; Hersey P; Zhang XD Cell Death Dis; 2013 Jun; 4(6):e655. PubMed ID: 23744355 [TBL] [Abstract][Full Text] [Related]
5. HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. Emmons MF; Faião-Flores F; Sharma R; Thapa R; Messina JL; Becker JC; Schadendorf D; Seto E; Sondak VK; Koomen JM; Chen YA; Lau EK; Wan L; Licht JD; Smalley KSM Cancer Res; 2019 Jun; 79(11):2947-2961. PubMed ID: 30987999 [TBL] [Abstract][Full Text] [Related]
6. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma. Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906 [TBL] [Abstract][Full Text] [Related]
8. Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors. Lai F; Jiang CC; Farrelly ML; Zhang XD; Hersey P Melanoma Res; 2012 Jun; 22(3):244-51. PubMed ID: 22516966 [TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Zhang XD; Gillespie SK; Borrow JM; Hersey P Mol Cancer Ther; 2004 Apr; 3(4):425-35. PubMed ID: 15078986 [TBL] [Abstract][Full Text] [Related]
10. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615 [TBL] [Abstract][Full Text] [Related]
11. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Shao Y; Aplin AE Cell Death Differ; 2012 Dec; 19(12):2029-39. PubMed ID: 22858545 [TBL] [Abstract][Full Text] [Related]
12. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Woods DM; Woan K; Cheng F; Wang H; Perez-Villarroel P; Lee C; Lienlaf M; Atadja P; Seto E; Weber J; Sotomayor EM; Villagra A Melanoma Res; 2013 Oct; 23(5):341-8. PubMed ID: 23963286 [TBL] [Abstract][Full Text] [Related]
13. Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma. Tseng HY; Dreyer J; Emran AA; Gunatilake D; Pirozyan M; Cullinane C; Dutton-Regester K; Rizos H; Hayward NK; McArthur G; Hersey P; Tiffen J; Gallagher S Int J Cancer; 2020 Oct; 147(8):2176-2189. PubMed ID: 32249419 [TBL] [Abstract][Full Text] [Related]
14. BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma. Paoluzzi L; Hanniford D; Sokolova E; Osman I; Darvishian F; Wang J; Bradner JE; Hernando E Cancer Med; 2016 Jun; 5(6):1183-93. PubMed ID: 27169980 [TBL] [Abstract][Full Text] [Related]
15. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro. Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071 [TBL] [Abstract][Full Text] [Related]
16. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells. Haydn T; Metzger E; Schuele R; Fulda S Cell Death Dis; 2017 Jun; 8(6):e2879. PubMed ID: 28617441 [TBL] [Abstract][Full Text] [Related]
17. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer. Ruscetti M; Dadashian EL; Guo W; Quach B; Mulholland DJ; Park JW; Tran LM; Kobayashi N; Bianchi-Frias D; Xing Y; Nelson PS; Wu H Oncogene; 2016 Jul; 35(29):3781-95. PubMed ID: 26640144 [TBL] [Abstract][Full Text] [Related]
18. Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance. Krumm A; Barckhausen C; Kücük P; Tomaszowski KH; Loquai C; Fahrer J; Krämer OH; Kaina B; Roos WP Cancer Res; 2016 May; 76(10):3067-77. PubMed ID: 26980768 [TBL] [Abstract][Full Text] [Related]
19. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters. Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541 [TBL] [Abstract][Full Text] [Related]
20. Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells. Enßle JC; Boedicker C; Wanior M; Vogler M; Knapp S; Fulda S Cancer Lett; 2018 Aug; 428():160-172. PubMed ID: 29709701 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]